Efgartigimod, an FcRn antagonist initially developed to treat autoimmune conditions such as myasthenia gravis and immune thrombocytopenic purpura, has shown promising efficacy in preclinical models of metabolic diseases (5, 23, 123). The gene discussed is FCGRT; the disease is metabolic disease.